Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 31, 2021
Issuance Date: April 28, 2021
GSK reported Q1 2021 results reflecting the anticipated impact of the COVID-19 pandemic, including disruptions to vaccination programs and "pantry-loading" comparisons from the prior year. The company remains on track to separate its Consumer Healthcare business into a standalone entity in 2022.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £7,418m | £9,090m | -18% | -15% |
| Total Operating Profit | £1,693m | £2,014m | -16% | -8% |
| Total Operating Margin | 22.8% | 22.2% | - | - |
| Adjusted Operating Profit | £1,881m | £2,675m | -30% | -23% |
| Adjusted Operating Margin | 25.4% | 29.5% | - | - |
| Total EPS | 21.5p | 31.5p | -32% | -25% |
| Adjusted EPS | 22.9p | 37.7p | -39% | -33% |
| Net Cash from Operations | £331m | £965m | -66% | - |
| Free Cash Flow | (£3m) | £531m | >-100% | - |
| Net Debt | £21,402m | £26,668m | - | - |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates.
Material Changes vs. Prior Period
- Pharmaceuticals: Turnover declined 12% AER (-8% CER). New and Specialty products grew 3% CER, driven by Respiratory (+24% CER), Immuno-inflammation (+26% CER), and Oncology (+38% CER). HIV sales declined 11% CER due to prior-year stocking and tender phasing, though two-drug regimens grew 41% CER.
- Vaccines: Turnover fell 32% AER (-30% CER), primarily due to government prioritization of COVID-19 vaccinations impacting Shingrix (-47% CER) and other routine immunizations.
- Consumer Healthcare: Turnover dropped 19% AER (-16% CER). Excluding divested brands, sales declined 9% CER due to a weak cold/flu season and high prior-year comparators from pandemic-related stocking.
- Profitability: Adjusted operating margin decreased 2.9 percentage points on a CER basis, reflecting sales declines and increased R&D investment, partially offset by cost controls and a favorable legal settlement.
Guidance, Outlook, and Risks
- 2021 Guidance: Reconfirmed. GSK expects Adjusted EPS to decline by a mid to high-single digit percentage at CER for the full year.
- 2022 Outlook: Unchanged. Management expects meaningful improvements in revenues and margins.
- Segment Outlook:
- Pharmaceuticals: Expected to grow flat to low-single digits at CER.
- Vaccines: Expected to grow flat to low-single digits at CER, with strong recovery anticipated in H2 2021 as healthcare systems normalize.
- Consumer Healthcare: Expected to grow low to mid-single digits at CER (excluding divested brands).
- Dividends: Q1 interim dividend of 19p declared. Full-year 2021 dividend expected to remain at 80p per share. A new distribution policy for 2022 will be announced in June.
- Risks & Contingencies:
- COVID-19: Ongoing uncertainty regarding pandemic duration, supply chain continuity, and clinical trial impacts.
- Legal: Aggregate provision for legal disputes is £0.2 billion. No significant new developments reported.
- Currency: Stronger Sterling negatively impacted reported growth. If period-end rates hold, estimated negative impact on 2021 turnover growth is 5%.
Investor Verification Checklist
- Shingrix Recovery: Verify the trajectory of Shingrix sales in H2 2021 as COVID-19 vaccination prioritization eases.
- Consumer Separation: Monitor progress on the separation of the Consumer Healthcare business, including the June 23 Investor Update regarding strategy and capital allocation.
- Pipeline Milestones: Track regulatory approvals and trial data for key assets: Cabenuva (HIV), RSV vaccine, and GSK '294 (asthma).
- Contingent Consideration: Review the fair value movements of the ViiV Healthcare contingent consideration liability (£5,277m at March 31, 2021), which impacts Total EPS but not Adjusted EPS.
- Free Cash Flow: Assess the turnaround in free cash flow generation given the Q1 outflow of £3m compared to a £531m inflow in Q1 2020.